Evidence map›Paper›PMID 41995791›Full record

ArticleDiscover oncology2026

Polycationic dendrimers synergizes with gefitinib to overcome EGFR

Adriana Cruz, Bruna Abreu, Cindy Mendes, Isabel Lemos, Catarina Freitas-Dias, Rafael Gomes, Bruna Sousa, Filipe Gonçalves, José S Ramalho, Duarte C Barral and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adriana Cruz *iBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Av. Rovisco Pais 1, Lisboa, 1049-001, Portugal.
Bruna Abreu *iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Cindy MendesiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Isabel LemosiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Catarina Freitas-DiasiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Rafael GomesiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Bruna SousaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Filipe GonçalvesiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
José S RamalhoiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Duarte C BarraliNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal.
Vasco D B BonifácioiBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Av. Rovisco Pais 1, Lisboa, 1049-001, Portugal. vasco.bonifacio@tecnico.ulisboa.pt.
Jacinta SerpaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisbon, 1169-056, Portugal. jacinta.serpa@nms.unl.pt.

Funding

Fundação para a Ciência e a Tecnologia UIDB/04462/2020
6 · The paper itself

Abstract

Lung cancer is a heterogeneous disease and the leading cause of cancer-related deaths worldwide. The aggressiveness of non-small-cell lung cancer (NSCLC) is often associated with oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway. Among the most prevalent mutations in NSCLC, epidermal growth factor receptor 1 (EGFR) and Kirsten rat sarcoma (KRAS) alterations play a key role in cancer progression and patient survival. In this study, we investigated the influence of EGFR and KRAS mutational status on the response to polycationic core-shell dendrimers, using NSCLC cell lines harboring different EGFR and KRAS profiles. Cells were treated with PURE

Indexed as

CAMEGFR mutationsKRAS mutationsNon-small cell lung cancer (NSCLC)Polycationic polyurea (PURE) dendrimersTyrosine-kinase inhibitors

Identifiers

PMID41995791
PMCPMC13216407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.